Lenvatinib Promotes Metabolic Reprogramming Through RTK to Inhibit Hepatocellular Carcinoma Proliferation and Metastasis

Xiaofang Zhao; Shengxiang Yan; Jing Meng; Limin Wang

doi:10.1111/hepr.70164

April 14, 2026Hepatology Research

Lenvatinib Promotes Metabolic Reprogramming Through RTK to Inhibit Hepatocellular Carcinoma Proliferation and Metastasis

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to investigate how lenvatinib affects lipid metabolism and inhibits hepatocellular carcinoma (HCC) proliferation and metastasis.
Analyzed the effects of lenvatinib on HCC cells
Examined the role of the PDGF/GFR-MAPK-PLA2G4E axis
Explored potential for combination therapies focusing on metabolic pathways
Lenvatinib effectively inhibits HCC proliferation and metastasis
Regulated lipid metabolism through PDGF/GFR-MAPK-PLA2G4E pathway
Proposed new combination therapies targeting metabolic pathways for improved HCC treatment

Implication

Lenvatinib inhibits hepatocellular carcinoma by regulating lipid metabolism, suggesting new treatment strategies.

Abstract

These findings establish that lenvatinib inhibits HCC by regulating lipid metabolism through the PDGF/GFR-MAPK-PLA2G4E axis, expanding the mechanistic understanding of RTK inhibitors and proposing metabolic pathway-targeted combination therapies for HCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhao et al. (2026) studied this question.

synapsesocial.com/papers/69e07e582f7e8953b7cbf549 https://doi.org/10.1111/hepr.70164

View Full Paper

Ask AI

Bookmark

Share

Lenvatinib Promotes Metabolic Reprogramming Through RTK to Inhibit Hepatocellular Carcinoma Proliferation and Metastasis

Key Points

Implication

Abstract

Discussion

Cite This Study

Lenvatinib Promotes Metabolic Reprogramming Through RTK to Inhibit Hepatocellular Carcinoma Proliferation and Metastasis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading